ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

Science Signaling

Volumn 9, Issue 415, 2016, Pages

  Ishizawa, Jo ^a   Kojima, Kensuke ^a,b   Chachad, Dhruv ^a   Ruvolo, Peter ^a   Ruvolo, Vivian ^a   Jacamo, Rodrigo O ^a   Borthakur, Gautam ^a   Mu, Hong ^a   Zeng, Zhihong ^a   Tabe, Yoko ^a,c   Allen, Joshua E ^d   Wang, Zhiqiang ^a   Ma, Wencai ^a   Lee, Hans C ^a   Orlowski, Robert ^a   Sarbassov, Dos D ^a   Lorenzi, Philip L ^a   Huang, Xuelin ^a   Neelapu, Sattva S ^a   McDonnell, Timothy ^a   Miranda, Roberto N ^a   Wang, Michael ^a   Kantarjian, Hagop ^a   Konopleva, Marina ^a   Davis, R Eric ^a   Andreeff, Michael ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SAGA UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Oncoceutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ANTINEOPLASTIC AGENT; BORTEZOMIB; IBRUTINIB; INITIATION FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; ONC 201; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG; VENETOCLAX; ATF4 PROTEIN, MOUSE; FUSED HETEROCYCLIC RINGS; TIC10 COMPOUND;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER PROGNOSIS; CANCER STEM CELL; CELL CYCLE ARREST; CELL LINE; CONTROLLED STUDY; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HUMAN; LEUKEMIA CELL; LEUKEMIC STEM CELL; MANTLE CELL LYMPHOMA; MOLECULE; MOUSE; MYELOID LEUKEMIA CELL LINE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN INDUCTION; STRESS; TUMOR ENGRAFTMENT; UNFOLDED PROTEIN RESPONSE; ANIMAL; DNA DAMAGE; DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, MANTLE-CELL; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ACTIVATING TRANSCRIPTION FACTOR 4; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DNA DAMAGE; HEMATOLOGIC NEOPLASMS; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, MANTLE-CELL; MICE;

EID: 84959142802     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aac4380     Document Type: Article

References (75)

1. The Cancer Genome Atlas Research Network, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074 (2013).
2. U. Krug, A. Ganser, H. P. Koeffler, Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21, 3475-3495 (2002).
3. F. G. Rücker, R. F. Schlenk, L. Bullinger, S. Kayser, V. Teleanu, H. Kett, M. Habdank, C.-M. Kugler, K. Holzmann, V. I. Gaidzik, P. Paschka, G. Held, M. von Lilienfeld-Toal, M. Lübbert, S. Fröhling, T. Zenz, J. Krauter, B. Schlegelberger, A. Ganser, P. Lichter, K. Döhner, H. Döhner, TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 119, 2114-2121 (2012).
4. D. Rossi, H. Khiabanian, V. Spina, C. Ciardullo, A. Bruscaggin, R. Famà, S. Rasi, S. Monti, C. Deambrogi, L. De Paoli, J.Wang, V. Gattei, A. Guarini, R. Foà, R. Rabadan, G. Gaidano, Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 123, 2139-2147 (2014).
5. K.-J. Cheung, D. E. Horsman, R. D. Gascoyne, The significance of TP53 in lymphoid malignancies: Mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br. J. Haematol. 146, 257-269 (2009).
6. D. Grimwade, R. K. Hills, A. V. Moorman, H. Walker, S. Chatters, A. H. Goldstone, K. Wheatley, C. J. Harrison, A. K. Burnett; National Cancer Research Institute Adult Leukaemia Working Group, Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116, 354-365 (2010).
7. V. Grossmann, S. Schnittger, A. Kohlmann, C. Eder, A. Roller, F. Dicker, C. Schmid, C.-M. Wendtner, P. Staib, H. Serve, K. A. Kreuzer, W. Kern, T. Haferlach, C. Haferlach, A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 120, 2963-2972 (2012).
8. A. M. Halldórsdóttir, A. Lundin, F. Murray, L.Mansouri, S. Knuutila, C. Sundström, A. Laurell, H. Ehrencrona, B. Sander, R. Rosenquist, Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. Leukemia 25, 1904-1908 (2011).
9. L. Hernandez, T. Fest, M. Cazorla, J. Teruya-Feldstein, F. Bosch, M. A. Peinado, M. A. Piris, E. Montserrat, A. Cardesa, E. S. Jaffe, E. Campo, M. Raffeld, p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87, 3351-3359 (1996).
10. F. Rubio-Moscardo, J. Climent, R. Siebert, M. A. Piris, J. I. Martín-Subero, I. Nieländer, J. Garcia-Conde, M. J. S. Dyer, M. J. Terol, D. Pinkel, J. A. Martinez-Climent, Mantlecell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105, 4445-4454 (2005).
11. J. E. Allen, G. Krigsfeld, L. Patel, P. A. Mayes, D. T. Dicker, G. S. Wu, W. S. El-Deiry, Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol. Cancer 14, 99 (2015).
12. J. E. Allen, G. Krigsfeld, P. A. Mayes, L. Patel, D. T. Dicker, A. S. Patel, N. G. Dolloff, E. Messaris, K. A. Scata, W. Wang, J.-Y. Zhou, G. S. Wu, W. S. El-Deiry, Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci. Transl. Med. 5, 171ra117 (2013).
13. J. E. Allen, V. V. Prabhu, M. Talekar, A. P. J. van den Heuvel, B. Lim, D. T. Dicker, J. L. Fritz, A. Beck, W. S. El-Deiry, Genetic and pharmacological screens converge in identifying FLIP, BCL2 and IAP proteins as key regulators of sensitivity to the TRAIL-inducing anticancer agent ONC201/TIC10. Cancer Res. 75, 1668-1674 (2015).
14. V. V. Prabhu, J. E. Allen, D. T. Dicker, W. S. El-Deiry, Small-molecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem-like cells in an Akt/Foxo3a/ TRAIL-dependent manner. Cancer Res. 75, 1423-1432 (2015).
15. M. M. Ho, D. E. Hogge, V. Ling, MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Exp. Hematol. 36, 433-442 (2008).
16. D. Drach, S. Zhao, J. Drach, R. Mahadevia, C. Gattringer, H. Huber, M. Andreeff, Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80, 2729-2734 (1992).
17. E. A. Obeng, L. M. Carlson, D. M. Gutman, W. J. Harrington Jr., K. P. Lee, L. H. Boise, Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907-4916 (2006).
18. P. Jain, M. Keating, W. Wierda, Z. Estrov, A. Ferrajoli, N. Jain, B. George, D. James, H. Kantarjian, J. Burger, S. O'Brien, Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 125, 2062-2067 (2015).
19. N. A. Pereira, Z. Song, Some commonly used caspase substrates and inhibitors lack the specificity required to monitor individual caspase activity. Biochem. Biophys. Res. Commun. 377, 873-877 (2008).
20. W. Ma, D. Yang, Y. Gu, X. Guo, W. Zhao, Z. Guo, Finding disease-specific coordinated functions by multi-function genes: Insight into the coordination mechanisms in diseases. Genomics 94, 94-100 (2009).
21. D. Krige, L. A. Needham, L. J. Bawden, N. Flores, H. Farmer, L. E. C. Miles, E. Stone, J. Callaghan, S. Chandler, V. L. Clark, P. Kirwin-Jones, V. Legris, J. Owen, T. Patel, S. Wood, G. Box, D. Laber, R. Odedra, A. Wright, L. M. Wood, S. A. Eccles, E. A. Bone, A. Ayscough, A. H. Drummond, CHR-2797: An antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res. 68, 6669-6679 (2008).
22. M. R. Janes, J. J. Limon, L. So, J. Chen, R. J. Lim, M. A. Chavez, C. Vu, M. B. Lilly, S. Mallya, S. T. Ong, M. Konopleva, M. B. Martin, P. Ren, Y. Liu, C. Rommel, D. A. Fruman, Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat. Med. 16, 205-213 (2010).
23. E. Chevet, C. Hetz, A. Samali, Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis. Cancer Discov. 5, 586-597 (2015).
24. H. J. Clarke, J. E. Chambers, E. Liniker, S. J. Marciniak, Endoplasmic reticulum stress in malignancy. Cancer Cell 25, 563-573 (2014).
25. W.-A. Wang, J. Groenendyk, M. Michalak, Endoplasmic reticulum stress associated responses in cancer. Biochim. Biophys. Acta 1843, 2143-2149 (2014).
26. H. P. Harding, Y. Zhang, H. Zeng, I. Novoa, P. D. Lu, M. Calfon, N. Sadri, C. Yun, B. Popko, R. Paules, D. F. Stojdl, J. C. Bell, T. Hettmann, J. M. Leiden, D. Ron, An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 11, 619-633 (2003).
27. G. Kroemer, G. Mariño, B. Levine, Autophagy and the integrated stress response. Mol. Cell 40, 280-293 (2010).
28. C. Appenzeller-Herzog, M. N. Hall, Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling. Trends Cell Biol. 22, 274-282 (2012).
29. M. Goldfinger, M. Shmuel, S. Benhamron, B. Tirosh, Protein synthesis in plasma cells is regulated by crosstalk between endoplasmic reticulum stress and mTOR signaling. Eur. J. Immunol. 41, 491-502 (2011).
30. H. Kato, S. Nakajima, Y. Saito, S. Takahashi, R. Katoh, M. Kitamura, mTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1-JNK pathway. Cell Death Differ. 19, 310-320 (2012).
31. M. Høyer-Hansen, M. Jäättelä, Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium. Cell Death Differ. 14, 1576-1582 (2007).
32. Y. J. Jeon, S. Khelifa, B. Ratnikov, D. A. Scott, Y. Feng, F. Parisi, C. Ruller, E. Lau, H. Kim, L. M. Brill, T. Jiang, D. L. Rimm, R. D. Cardiff, G. B. Mills, J. W. Smith, A. L. Osterman, Y. Kluger, Z. A. Ronai, Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. Cancer Cell 27, 354-369 (2015).
33. E. Bobrovnikova-Marjon, D. Pytel, M. J. Riese, L. P. Vaites, N. Singh, G. A. Koretzky, E. S. Witze, J. A. Diehl, PERK utilizes intrinsic lipid kinase activity to generate phosphatidic acid, mediate Akt activation, and promote adipocyte differentiation. Mol. Cell. Biol. 32, 2268-2278 (2012).
34. S. Kazemi, Z. Mounir, D. Baltzis, J. F. Raven, S. Wang, J.-L. Krishnamoorthy, O. Pluquet, J. Pelletier, A. E. Koromilas, A novel function of eIF2a kinases as inducers of the phosphoinositide-3 kinase signaling pathway. Mol. Biol. Cell 18, 3635-3644 (2007).
35. A. E. Koromilas, Z. Mounir, Control of oncogenesis by eIF2a phosphorylation: Implications in PTEN and PI3K-Akt signaling and tumor treatment. Future Oncol. 9, 1005-1015 (2013).
36. Z. Mounir, J. L. Krishnamoorthy, S. Wang, B. Papadopoulou, S. Campbell, W. J. Muller, M. Hatzoglou, A. E. Koromilas, Akt determines cell fate through inhibition of the PERKeIF2a phosphorylation pathway. Sci. Signal. 4, ra62 (2011).
37. K. Rajesh, J. Krishnamoorthy, U. Kazimierczak, C. Tenkerian, A. I. Papadakis, S. Wang, S. Huang, A. E. Koromilas, Phosphorylation of the translation initiation factor eIF2a at serine 51 determines the cell fate decisions of Akt in response to oxidative stress. Cell Death Dis. 6, e1591 (2015).
38. F. Xiao, Z. Huang, H. Li, J. Yu, C. Wang, S. Chen, Q. Meng, Y. Cheng, X. Gao, J. Li, Y. Liu, F. Guo, Leucine deprivation increases hepatic insulin sensitivity via GCN2/ mTOR/S6K1 and AMPK pathways. Diabetes 60, 746-756 (2011).
39. S.-D. Chou, T. Prince, J. Gong, S. K. Calderwood, mTOR is essential for the proteotoxic stress response, HSF1 activation and heat shock protein synthesis. PLOS One 7, e39679 (2012).
40. S. Santagata, M. L. Mendillo, Y.-c. Tang, A. Subramanian, C. C. Perley, S. P. Roche, B. Wong, R. Narayan, H. Kwon, M. Koeva, A. Amon, T. R. Golub, J. A. Porco Jr., L. Whitesell, S. Lindquist, Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science 341, 1238303 (2013).
41. R. B. Hamanaka, B. S. Bennett, S. B. Cullinan, J. A. Diehl, PERK and GCN2 contribute to eIF2a phosphorylation and cell cycle arrest after activation of the unfolded protein response pathway. Mol. Biol. Cell 16, 5493-5501 (2005).
42. N. Donnelly, A. M. Gorman, S. Gupta, A. Samali, The eIF2a kinases: Their structures and functions. Cell. Mol. Life Sci. 70, 3493-3511 (2013).
43. Y. Sancak, T. R. Peterson, Y. D. Shaul, R. A. Lindquist, C. C. Thoreen, L. Bar-Peled, D. M. Sabatini, The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320, 1496-1501 (2008).
44. S. J. Marciniak, C. Y. Yun, S. Oyadomari, I. Novoa, Y. Zhang, R. Jungreis, K. Nagata, H. P. Harding, D. Ron, CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev. 18, 3066-3077 (2004).
45. R. Sano, J. C. Reed, ER stress-induced cell death mechanisms. Biochim. Biophys. Acta 1833, 3460-3470 (2013).
46. I. Tabas, D. Ron, Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat. Cell Biol. 13, 184-190 (2011).
47. X. Wang, C. G. Proud, A novel mechanism for the control of translation initiation by amino acids, mediated by phosphorylation of eukaryotic initiation factor 2B. Mol. Cell. Biol. 28, 1429-1442 (2008).
48. C. W. Woo, L. Kutzler, S. R. Kimball, I. Tabas, Toll-like receptor activation suppresses ER stress factor CHOP and translation inhibition through activation of eIF2B. Nat. Cell Biol. 14, 192-200 (2012).
49. S. L. Lehman, S. Ryeom, C. Koumenis, Signaling through alternative Integrated Stress Response pathways compensates for GCN2 loss in a mouse model of soft tissue sarcoma. Sci. Rep. 5, 11781 (2015).
50. H. P. Harding, I. Novoa, Y. Zhang, H. Zeng, R. Wek, M. Schapira, D. Ron, Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol. Cell 6, 1099-1108 (2000).
51. K. M. Vattem, R. C. Wek, Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 101, 11269-11274 (2004).
52. P. D. Lu, H. P. Harding, D. Ron, Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response. J. Cell Biol. 167, 27-33 (2004).
53. D. Han, A. G. Lerner, L. Vande Walle, J.-P. Upton, W. Xu, A. Hagen, B. J. Backes, S. A. Oakes, F. R. Papa, IRE1a kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. Cell 138, 562-575 (2009).
54. C. Leung-Hagesteijn, N. Erdmann, G. Cheung, J. J. Keats, A. K. Stewart, D. E. Reece, K. C. Chung, R. E. Tiedemann, Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 24, 289-304 (2013).
55. A. Y. Choo, S.-O. Yoon, S. G. Kim, P. P. Roux, J. Blenis, Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. U.S.A. 105, 17414-17419 (2008).
56. J. Brugarolas, K. Lei, R. L. Hurley, B. D. Manning, J. H. Reiling, E. Hafen, L. A. Witters, L. W. Ellisen, W. G. Kaelin Jr., Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18, 2893-2904 (2004).
57. M. P. DeYoung, P. Horak, A. Sofer, D. Sgroi, L. W. Ellisen, Hypoxia regulates TSC1/ 2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 22, 239-251 (2008).
58. M. L. Whitney, L. S. Jefferson, S. R. Kimball, ATF4 is necessary and sufficient for ER stress-induced upregulation of REDD1 expression. Biochem. Biophys. Res. Commun. 379, 451-455 (2009).
59. R. Pan, L. J. Hogdal, J. M. Benito, D. Bucci, L. Han, G. Borthakur, J. Cortes, D. J. DeAngelo, L. Debose, H. Mu, H. Döhner, V. I. Gaidzik, I. Galinsky, L. S. Golfman, T. Haferlach, K. G. Harutyunyan, J. Hu, J. D. Leverson, G. Marcucci, M.Müschen, R. Newman, E. Park, P. P. Ruvolo, V. Ruvolo, J. Ryan, S. Schindela, P. Zweidler-McKay, R. M. Stone, H. Kantarjian, M. Andreeff, M. Konopleva, A. G. Letai, Selective BCL-2 inhibition by ABT- 199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 4, 362-375 (2014).
60. J. Ye, C. Koumenis, ATF4, an ER stress and hypoxia-inducible transcription factor and its potential role in hypoxia tolerance and tumorigenesis. Curr. Mol. Med. 9, 411-416 (2009).
61. M. S. Kilberg, J. Shan, N. Su, ATF4-dependent transcription mediates signaling of amino acid limitation. Trends Endocrinol. Metab. 20, 436-443 (2009).
62. I. Lassot, E. Ségéral, C. Berlioz-Torrent, H. Durand, L. Groussin, T. Hai, R. Benarous, F. Margottin-Goguet, ATF4 degradation relies on a phosphorylation-dependent interaction with the SCFbTrCP ubiquitin ligase. Mol. Cell. Biol. 21, 2192-2202 (2001).
63. K. Ameri, C. E. Lewis, M. Raida, H. Sowter, T. Hai, A. L. Harris, Anoxic induction of ATF-4 through HIF-1-independent pathways of protein stabilization in human cancer cells. Blood 103, 1876-1882 (2004).
64. C. L. B. Kline, A. P. J. van den Heuvel, J. E. Allen, V. V. Prabhu, D. T. Dicker, W. S. El-Deiry, ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by the eIF2a kinases, HRI and PKR. Sci. Signal. 8, (2015).
65. E. H.-Y. A Cheng, M. C.Wei, S.Weiler, R. A. Flavell, T.W. Mak, T. Lindsten, S. J. Korsmeyer, BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAKmediated mitochondrial apoptosis. Mol. Cell 8, 705-711 (2001).
66. H. Akl, T. Vervloessem, S. Kiviluoto, M. Bittremieux, J. B. Parys, H. De Smedt, G. Bultynck, A dual role for the anti-apoptotic Bcl-2 protein in cancer: Mitochondria versus endoplasmic reticulum. Biochim. Biophys. Acta 1843, 2240-2252 (2014).
67. J. F. Seymour, M. S. Davids, J. M. Pagel, B. S. Kahl, W. G. Wierda, S. Puvvada, J. F. Gerecitano, T. J. Kipps, M. A. Anderson, D. C. S. Huang, N. Rudersdorf, L. A. Gressick, N. P. Montalvo, J. Yang, M. Zhu, M. Dunbar, E. Cerri, S. H. Enschede, R. Humerickhouse, A. W. Roberts, ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete response rate and durable disease control. J. Clin. Oncol. 32, 7015 (2014).
68. M. Konopleva, D. A. Pollyea, J. Potluri, B. J. Chyla, T. Busman, E. McKeegan, A. Salem, M. Zhu, J. L. Ricker, W. Blum, C. D. DiNardo, M. Dunbar, R. Kirby, N. Falotico, J. D. Leverson, R. A. Humerickhouse, M. Mabry, R. M. Stone, H. M. Kantarjian, A. G. Letai, A phase 2 study of ABT-199 (GDC-0199) in patients with acute myelogenous leukemia (AML). Blood 124, 118 (2014).
69. K. Kojima, S. M. Kornblau, V. Ruvolo, A. Dilip, S. Duvvuri, R. E. Davis, M. Zhang, Z.Wang, K. R. Coombes, N. Zhang, Y. H. Qiu, J. K. Burks, H. Kantarjian, S. Shacham, M. Kauffman, M. Andreeff, Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 121, 4166-4174 (2013).
70. K. Kojima, M. Konopleva, I. J. Samudio, M. Shikami, M. Cabreira-Hansen, T. McQueen, V. Ruvolo, T. Tsao, Z. Zeng, L. T. Vassilev, M. Andreeff, MDM2 antagonists induce p53- dependent apoptosis in AML: Implications for leukemia therapy. Blood 106, 3150-3159 (2005).
71. J. Ishizawa, S. Kuninaka, E. Sugihara, H. Naoe, Y. Kobayashi, T. Chiyoda, A. Ueki, K. Araki, K.-i. Yamamura, Y. Matsuzaki, H. Nakajima, Y. Ikeda, S. Okamoto, H. Saya, The cell cycle regulator Cdh1 controls the pool sizes of hematopoietic stem cells and mature lineage progenitors by protecting from genotoxic stress. Cancer Sci. 102, 967-974 (2011).
72. M. Yoshimura, J. Ishizawa, V. Ruvolo, A. Dilip, A. Quintás-Cardama, T. J. McDonnell, S. S. Neelapu, L. W. Kwak, S. Shacham, M. Kauffman, Y. Tabe, M. Yokoo, S. Kimura, M. Andreeff, K. Kojima, Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci. 105, 795-801 (2014).
73. W.-L. Lai, N.-S. Wong, The PERK/eIF2a signaling pathway of unfolded protein response is essential for N-(4-hydroxyphenyl)retinamide (4HPR)-induced cytotoxicity in cancer cells. Exp. Cell Res. 314, 1667-1682 (2008).
74. W. Ma, M. Wang, Z.-Q. Wang, L. Sun, D. Graber, J. Matthews, R. Champlin, Q. Yi, R. Z. Orlowski, L. W. Kwak, D. M.Weber, S. K. Thomas, J. Shah, S. Kornblau, R. E. Davis, Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol. Biomarkers Prev. 19, 2445-2452 (2010).
75. A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P. Mesirov, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545-15550 (2005).